Research and Markets: Global Indolent Lymphoma Therapeutics Pipeline Review 2015 - 21 Companies & 24 Drug Profiles

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/4l752v/indolent_lymphoma) has announced the addition of the "Indolent Lymphoma - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

  • Amgen Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • BioMedics Japan Inc.
  • Biothera, Inc.
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Eagle Pharmaceuticals, Inc.
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Infinity Pharmaceuticals, Inc.
  • Juno Therapeutics Inc.
  • Kite Pharma, Inc.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Merck KGaA
  • MorphoSys AG
  • Pharmacyclics, Inc.
  • Sandoz Inc.

Drug Profiles

  • bendamustine hydrochloride
  • bendamustine hydrochloride SI
  • BI-836826
  • blinatumomab
  • BM-ca
  • copanlisib
  • DI-B4
  • duvelisib
  • GS-9973
  • ibrutinib
  • idelalisib
  • Imprime PGG
  • INCB-050465
  • INCB-39110
  • INCB-40093
  • JCAR-015
  • KTE-C19 CAR
  • lenalidomide
  • MEDI-551
  • MOR-208
  • obinutuzumab
  • otlertuzumab
  • rituximab biosimilar
  • vorinostat

For more information visit http://www.researchandmarkets.com/research/4l752v/indolent_lymphoma

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology